For advanced oncology programs, managing complex CRISPR-edited rodent models is a significant logistical and scientific challenge that directly impacts data integrity and program timelines. Franklin Biolabs provides specialized, GxP-compliant colony management services designed to support these advanced models. Our approach ensures the genetic stability, health, and availability of study-ready cohorts, de-risking preclinical development and preserving the validity of translational data packages intended for an 18-24 month IND submission.

The Requirement for Precision in Genetically Engineered Model (GEM) Management

The precision of CRISPR/Cas9 technology has enabled the development of genetically engineered models that more accurately recapitulate human cancers. However, the management of these colonies introduces significant complexity. Spontaneous genetic drift, breeding inefficiencies, and inconsistent health status can introduce variables that confound study results and compromise the integrity of a preclinical data package.

Rigorous colony maintenance is a scientific function that underpins the validity of all subsequent in vivo research. Without structured oversight, subtle changes in the model can lead to irreproducible results, delaying key program decisions and extending development timelines.

Integrated Colony Management and Study Execution

Franklin Biolabs provides a structured framework for managing valuable and complex rodent lines, ensuring that research teams have access to well-characterized, study-ready animals. Our operational agility accelerating in vivo success is built on several core activities:

• Genotyping and Cohort Assembly: We establish robust, validated genotyping assays to confirm genetic modifications and screen progeny efficiently. This allows for the rapid assembly of age- and sex-matched cohorts with confirmed genotypes.

• Health and Welfare Monitoring: Our veterinary staff and technical teams conduct continuous health monitoring to ensure animal welfare and the scientific validity of the models, particularly for lines that may have compromised health phenotypes.

• Data Integrity and Traceability: All colony management activities, from breeding records to health checks, are documented within a GxP-compliant framework. This provides a complete, auditable history for each animal used in a study.

• Cryopreservation and Archiving: To safeguard against colony loss and genetic drift, we offer cryopreservation services for sperm and embryos, securing your investment in model development for future use.

Supporting Advanced Therapeutic Modalities

Effective colony management provides the foundation for evaluating novel therapeutic platforms. The ability to assess mutation-independent strategies, such as the LNP-mRNA therapies investigated for metabolic disorders (PMID: 39001827), depends entirely on the availability of robust, genetically consistent animal models. Reproducing and expanding these lines is a prerequisite for generating the reliable pharmacology data needed for IND-enabling studies.

This approach mirrors the value of centralized resource programs, which provide the core infrastructure necessary to translate complex biological insights into clinical candidates (PMID: 29130351). The scientific leadership at Franklin Biolabs, including key personnel from world-renowned academic vector cores such as the University of Pennsylvania program, brings this institutional expertise to every sponsor program.